[A practical study of the efficacy of a delayed-action preparation of @entity2049 ( @entity2049 CR 400) in the treatment of XXXX with @entity302 ].

@entity1 @entity410 @entity2050 @entity75 @entity302 @entity1296 @entity892 @entity10 @entity2049 @entity2055
INTRODUCTION: @entity2049 ( @entity2050 ) is the first choice antiepileptic drug in the treatment of partial @entity410 . Many clinical studies show high efficacy and good tolerance of @entity2050 in the majority of @entity1 . However, poor water solubility and erratic absorption as well as autoinduction of its metabolism, cause wide and unpredictable fluctuations in @entity2050 serum concentration. In order to avoid these problems controlled-release formulations of @entity2050 (Tegretol CR 400) were developed. PURPOSE: The aim of this study was to evaluate the efficacy, tolerance and practicality of the therapy of partial @entity410 in adults with controlled-release @entity2050 (Tegretol CR 400). @entity1 AND METHODS: Over a three-year period we conducted an open pragmatic study of controlled-release @entity2050 in the therapy of 141 adult @entity1 with established diagnosis of localized related @entity302 . @entity1 with progressive @entity75 were excluded. All @entity1 had unacceptable @entity410 frequency and were divided into four groups: 1) 34 with newly-diagnosed @entity302 ; 2) 42 with chronic @entity302 and no previous antiepileptic medication; 3) 27 with chronic @entity302 previously treated with conventional preparations of @entity2049 ( @entity2050 ); and 4) 38 with chronic @entity302 previously treated with other antiepileptic medications. @entity1 were switched to controlled-release @entity2050 and the dosage was slowly adjusted. Baseline evaluation included the analysis of efficacy, tolerance and practicality of the controlled-release @entity2050 therapy. Three categories of efficiency were defined: 1) successful ( @entity1 without @entity410 ); 2) partially successful ( @entity1 with improvement of at least 50% in frequency and severity of @entity410 ); and 3) unsuccessful therapy (same or worse than before controlled-release @entity2050 ). Tolerance and practicity were evaluated through the analysis of side effects and frequency of daily doses, respectively. These variables were compared to the corresponding ones after a period of at least three months of full dosage controlled-release @entity2050 therapy. RESULTS: In all four groups the therapy was successful in 76%, 52%, 30% and 29%, partially successful in 18%, 43%, 30% and 32%, and unsuccessful in 6%, S%, 40% and 39%, respectfully. Side effects occurred less frequently in all 4 groups during the therapy with controlled-release @entity2050 . We found reduced frequency of drug administration (once or twice daily) in 97.9% of our @entity1 . DISCUSSION: Due to its slow and irregular absorption, short half life, wide and unpredictable fluctuation in plasma levels @entity2050 has decreased ability to control @entity410 , with the appearance of the intermittent side-effects such as @entity892 , @entity2055 , @entity10 and @entity1296 . Controlled-release formulation of @entity2050 sustains stable absorption and reduces fluctuations in @entity2049 serum concentration. Steady serum levels permit to the majority of @entity1 to tolerate a higher total daily dose by reducing peak-dependent side-effects and improve compliance as a result of less frequent daily doses (1 or 2). CONCLUSION: In @entity1 with partial @entity410 controlled-release vs. conventional @entity2049 had better efficiency, based on an excellent tolerance, favorable daily dosage and superior compliance.
